Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Sobering statistics in oncology trials

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Sep 27, 2021 1:52pm

105 Views

Post# 33924739

RE:RE:RE:RE:RE:RE:RE:Sobering statistics in oncology trials

You can always hope that is the case!

palinc2000 wrote: With regards to oncology not necessarily waiting for all conclusions to be proven but waiting for some data ,,,maybe going as far as any data ,,,,
BTW should I conclude that you have added to your position ahead of results from oncology?

palinc2000 wrote: The more than hope stems from Tesamorelin already established undeniable safety record , known phase 2 clinical trial results ,approved Protocol for Phase 3 from both FDA and EMA ,failures from other Nash involved companies,KOL s strong endorsement, unmet medical needs and the hundreds of articles posted mainly by Scarlett on Nash ,,,,and finally Paul going on record that he is searching for a partner and the fact that he alluded to getting funds thru other means is just a negotiation tactics imo,,,,,,ALL add up to an opportunity that Partners cant or wont pass up.....

SPCEO1 wrote: That is the problem with investing - if you wait until your conclusions are proven, there usually is no opportunity left to make a profit as others who were willing to make a bet on their analysis of a situation got those profits, and yes, sometimes losses too.

I am curious what the "more than hope" is that you have on a NASH partnership? I am only seeing evidence of a company looking for an alternative to a partnership.

palinc2000 wrote: You are drawing unproven conclusion imo...Setting yourself up for big disappoinment....
I have very minimal expectations for oncology and greater expectations for Nah,,
This explains why I dont lose any sleep on the current SP which as you point out in your weekly report card has had nice% appreciation in the last year,,

I still believe that increased revenues from the legacy drugs will provide as least as good price appreciation in the next year but probably much better .Nash partnering on not too bad terms is another possibility based on more than hope

SPCEO1 wrote: I suspect the fact the trial appears to be still ongoing mitigates the risk of problems related to the overaccumulation in healthy cells expressing sortilin. We are probably in the clear on that risk.

jeffm34 wrote:
it has a couple things going for it which will increase the odds of success greatly. They are using Docetaxel which already works and is approved. It doesn't even have to be more effective than Docetaxel alone. If it's only just as effective but at a lower dose meaning less side effects then it will still be approved. The only wild card is over accumulation in healthy cells expressing sortilin.

palinc2000 wrote: Very low [3.8%] success rate.....I fail to see any known hard facts in our own Phase 1 apart that it is still ongoing and dosing levels have increased but to unknown levels.What dont I get? Would love to get excited but I see nothing except hope

https://www.acsh.org/news/2020/06/11/clinical-trial-success-rates-phase-and-therapeutic-area-14845